%0 Journal Article %A Sudarsan Pothal %A Smrutirekha Swain %A Aurobindo Behera %A Gaurahari Pradhan %A Rekha Manjhi %A Pravati Dutta %T Treatment outcome among post TB obstructive airways diseases & COPD: A Prospective Cohort study %D 2020 %R 10.1183/13993003.congress-2020.489 %J European Respiratory Journal %P 489 %V 56 %N suppl 64 %X Title: Treatment outcome among Post TB Obstructive Airways Diseases & COPD : A Prospective Cohort Study.Background: Among the various sequelae of Pulmonary Tuberculosis, Obstructive airways disease is one of them. Since the pathophysiological processes in both Chronic Obstructive Pulmonary Disease (COPD) and Post Tubercular Obstructive Airways Disease (Post-TB OAD) are not entirely same, there is a need to explore further.Aim: To compare the frequency of exacerbation, decline rate of FEV1, frequency of hospitalization & mortality among COPD & Post TB OAD patients.Methods: This was a prospective cohort study; one cohort was COPD & another cohort was Post-TB OAD. COPD was diagnosed based on history of exposure to risk factor, symptoms & post-bronchodilator FEV1/FVC ratio<70%. Post-TB OAD was diagnosed based on history of pulmonary TB , symptoms & post bronchodilator FEV1/FVC ratio<70%. Both cohorts were treated based on Global Initiative for Chronic Obstructive Pulmonary Lung Diseases(GOLD-2017) guideline. Both cohorts were followed up every 3-monthly interval for up to 1 year.Result: 68 number of patients of post TB OAD and 66 COPD patients were taken into this study. The rate of decline of FEV1 from the time of enrolment to 1 year follow up was 0.27±0.28 litre in post TB OAD and 0.17±0.26 litre in COPD. There was increased frequency of exacerbation(3.52±1.83 vs 2.70±1.37), hospitalization rate(1.37±0.81 vs 0.97±0.94) and mortality rate(20.97% vs 9.09%) among post TB OAD in comparision to COPD.Conclusion: There was an increase in frequency of exacerbation, hospitalization rate & mortality rate among Post TB OAD compared to classical COPD.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 489.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). %U